Metformin induces apoptotic cytotoxicity depending on AMPK/PKA/GSK-3β-mediated c-FLIP_L degradation in non-small cell lung cancer

References

• LiuYHeCHuangXCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• ShiPLiuWTalaMetformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradationCell Discov201731701028480051
   PubMed Web of Science ®Google Scholar
• ZhengLYangWWuFPrognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinomaClin Cancer Res201319195372538023942093
   PubMed Web of Science ®Google Scholar
• HanGGongHWangYGuoSLiuKAMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cellCancer Biol Ther2015161778725456211
   PubMed Web of Science ®Google Scholar
• ShiWYXiaoDWangLTherapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagyCell Death Dis20123e27522378068
   PubMed Web of Science ®Google Scholar
• TomicTBottonTCerezoMMetformin inhibits melanoma development through autophagy and apoptosis mechanismsCell Death Dis20112e19921881601
   PubMed Web of Science ®Google Scholar
• HsiehSCTsaiJPYangSFTangMJHsiehYHMetformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expressionAmino Acids201446122809282225245054
   PubMed Web of Science ®Google Scholar
• PennatiMFoliniMZaffaroniNTargeting survivin in cancer therapy: fulfilled promises and open questionsCarcinogenesis20072861133113917341657
   PubMed Web of Science ®Google Scholar
• StorozhukYHopmansSNSanliTMetformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPKBr J Cancer2013108102021203223632475
   PubMed Web of Science ®Google Scholar
• LiKLLiLZhangPA multicenter double-blind phase II study of metformin with gefitinib as first-line therapy of locally advanced non-small-cell lung cancerClin Lung Cancer201718334034328065465
   PubMed Web of Science ®Google Scholar
• MorgilloFSassoFCDella CorteCMSynergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell linesClin Cancer Res201319133508351923695170
   PubMed Web of Science ®Google Scholar
• WangXChenKYuYMetformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinibOncotarget201786510906810907829312591
   PubMedGoogle Scholar
• GroenendijkFHMellemaWWvan der BurgESorafenib synergizes with metformin in NSCLC through AMPK pathway activationInt J Cancer201513661434144425080865
   PubMed Web of Science ®Google Scholar
• LiuYHeCHuangXMetformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolismOncotarget2017843752067521629088858
   PubMedGoogle Scholar
• LinCCYehHHHuangWLMetformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathwayAm J Respir Cell Mol Biol201349224125023526220
   PubMed Web of Science ®Google Scholar
• NazimUMMoonJHLeeJHActivation of autophagy flux by metformin downregulates cellular FLICE-like inhibitory protein and enhances TRAIL-induced apoptosisOncotarget2016717234682348126992204
   PubMedGoogle Scholar
• LinJGillAZahmSHMetformin use and survival after non-small cell lung cancer: a cohort study in the US Military health systemInt J Cancer2017141225426328380674
   PubMed Web of Science ®Google Scholar
• EvansJMDonnellyLAEmslie-SmithAMAlessiDRMorrisADMetformin and reduced risk of cancer in diabetic patientsBMJ200533075031304130515849206
   PubMed Web of Science ®Google Scholar
• TsaiMJYangCJKungYTMetformin decreases lung cancer risk in diabetic patients in a dose-dependent mannerLung Cancer201486213714325267165
   PubMed Web of Science ®Google Scholar
• PernicovaIKorbonitsMMetformin – mode of action and clinical implications for diabetes and cancerNat Rev Endocrinol201410314315624393785
   PubMed Web of Science ®Google Scholar
• PulitoCMoriFSacconiAMetformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activitiesCell Discov201731702228698800
   PubMed Web of Science ®Google Scholar
• BlandinoGValerioMCioceMMetformin elicits anticancer effects through the sequential modulation of DICER and c-MYCNat Commun2012386522643892
   PubMed Web of Science ®Google Scholar
• EikawaSNishidaMMizukamiSYamazakiCNakayamaEUdonoHImmune-mediated antitumor effect by type 2 diabetes drug, metforminProc Natl Acad Sci USA201511261809181425624476
   PubMed Web of Science ®Google Scholar
• MicheauOCellular FLICE-inhibitory protein: an attractive therapeutic target?Expert Opin Ther Targets20037455957312885274
   PubMed Web of Science ®Google Scholar
• IrmlerMThomeMHahneMInhibition of death receptor signals by cellular FLIPNature199738866381901959217161
   PubMed Web of Science ®Google Scholar
• ShirleySMicheauOTargeting c-FLIP in cancerCancer Lett2013332214115021071136
   PubMed Web of Science ®Google Scholar
• ShiSWangQXuJSynergistic anticancer effect of cisplatin and Chal-24 combination through IAP and c-FLIPL degradation, Ripoptosome formation and autophagy-mediated apoptosisOncotarget2015631640165125682199
   PubMed Web of Science ®Google Scholar
• XuJXuXShiSAutophagy-mediated degradation of IAPs and c-FLIP(L) potentiates apoptosis induced by combination of TRAIL and Chal-24J Cell Biochem201611751136114426448608
   PubMed Web of Science ®Google Scholar
• ZhangTWangXHeDJinXGuoPMetformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIPAnticancer Drugs201425888789724714080
   PubMed Web of Science ®Google Scholar
• JangJHSongIHSungEGLeeTJKimJYMetformin-induced apoptosis facilitates degradation of the cellular caspase 8 (FLICE)-like inhibitory protein through a caspase-dependent pathway in human renal cell carcinoma A498 cellsOncol Lett20181622030203830008897
   PubMed Web of Science ®Google Scholar
• HeWWangQXuJAttenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2-and RIPK1/RIP1-mediated MAPK8/JNK activationAutophagy20128121811182123051914
   PubMed Web of Science ®Google Scholar
• BeristainAGMolyneuxSDJoshiPAPKA signaling drives mammary tumorigenesis through SrcOncogene20153491160117324662820
   PubMed Web of Science ®Google Scholar
• MillerRAChuQXieJForetzMViolletBBirnbaumMJBiguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMPNature2013494743625626023292513
   PubMed Web of Science ®Google Scholar
• FangXYuSXLuYBastRCWoodgettJRMillsGBPhosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase AProc Natl Acad Sci USA20009722119601196511035810
   PubMed Web of Science ®Google Scholar
• LiMWangXMeintzerMKLaessigTBirnbaumMJHeidenreichKACyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3betaMol Cell Biol200020249356936311094086
   PubMed Web of Science ®Google Scholar
• SubramaniamKHirparaJLTucker-KelloggLTucker-KelloggGPervaizSFLIP: a flop for execution signalsCancer Lett2013332215115522781394
   PubMed Web of Science ®Google Scholar
• CaoJMengSChangELow concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK)J Biol Chem201428930204352044624928508
   PubMed Web of Science ®Google Scholar
• MengSCaoJHeQMetformin activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complexJ Biol Chem201529063793380225538235
   PubMed Web of Science ®Google Scholar
• GwakHKimYAnHDhanasekaranDNSongYSMetformin induces degradation of cyclin D1 via AMPK/GSK3β axis in ovarian cancerMol Carcinog201756234935827128966
   PubMed Web of Science ®Google Scholar